Concerned about African Swine Fever? Newport Labs does not use any raw materials from countries identified by the USDA as potential carriers of foreign animal diseases, including China.


Discover an easier way to manage isolates with this exclusive software tool tailored to veterinarians.

Use HerdPoint™ for easier isolate management and a more efficient nonadjacent approval process.

Learn More >

About Us

Custom Made Vaccines


Press Releases

New Software Streamlines Custom-Vaccine Management for Livestock Veterinarians
  • by
  • Sep 04, 2018

WORTHINGTON, Minn. (Sept. 4, 2018) — Newport Laboratories, Inc., a leader in livestock custom-made vaccines (CMVs), today launches HerdPoint,™ a new solution for veterinarians that streamlines the nonadjacent-herd approval process and ongoing isolate management, all from a mobile phone or computer.


Newport Laboratories is now part of Boehringer Ingelheim
  • by
  • Jun 12, 2018

DULUTH, Ga. — [June 12, 2018]

Boehringer Ingelheim (BI) is excited to announce that Newport Laboratories, Inc. in Worthington, Minnesota, is officially part of Boehringer Ingelheim’s animal health business unit.

Newport Laboratories enhances the service and product offerings for BI customers. By providing cutting-edge diagnostics like whole genome sequencing, metagenomics, and bioinformatics, Newport Laboratories crafts custom, autogenous vaccines that target the specific viruses or bacteria causing disease in individual livestock operations.


Randy Shirbroun talks pathology and prevention of diseases
  • by
  • Jun 24, 2016

WORTHINGTON, Minn. – Veterinarian Randy Shirbroun of Newport Laboratories Inc. addressed more than 200 bison producers regarding the pathology and prevention of diseases caused by Mycoplasma bovis. The producers had gathered for the 2016 National Bison Association Summer Conference held in June at Elk River, Minnesota. Shirbroun specializes in ruminant health issues including those seen in the American bison, which became the official U.S. national mammal in May.


Newport Laboratories releases new Mycoplasma bovis Test
  • by
  • Nov 09, 2015

Newport Laboratories, Inc. has developed a new multilocus sequence typing (MLST) technique for Mycoplasma bovis, a significant cause of disease in cattle. The new technology represents a major advancement over the previous diagnostic process and will provide increased resolution and a better assessment of genetic variation that may be associated with antigenic, or strain differences. 

This technological advancement utilizing molecular biology is yet another development to come from Newport Laboratories, Inc., a leader in cutting edge diagnostic technology and the manufacturer of autogenous, or custom-made vaccines.  The new MLST technique evaluates 10 variable genes associated with specific Mycoplasma bovis virulence factors, including several of the variable surface proteins (VSPs).

Vaccine TechnologyA New Era of
Vaccine Technology